<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Market News &#38; Stocks to Watch from StraightStocks &#187; Orbimed Advisors Llc;</title>
	<atom:link href="http://www.straightstocks.com/tag/orbimed-advisors-llc/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.straightstocks.com</link>
	<description>Leading Stock Market News, Opinions and Commentary</description>
	<lastBuildDate>Sat, 20 Mar 2010 06:40:09 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Hana Biosciences, Inc. (HNAB.OB) Announces $12.4 Million Private Placement</title>
		<link>http://www.straightstocks.com/investing-lessons/hana-biosciences-inc-hnab-ob-announces-12-4-million-private-placement/</link>
		<comments>http://www.straightstocks.com/investing-lessons/hana-biosciences-inc-hnab-ob-announces-12-4-million-private-placement/#comments</comments>
		<pubDate>Thu, 08 Oct 2009 14:26:08 +0000</pubDate>
		<dc:creator>QualityStocks</dc:creator>
				<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Small & Micro Cap]]></category>
		<category><![CDATA[acute lymphoblastic leukemia]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Cancer Treatment]]></category>
		<category><![CDATA[deadly disease]]></category>
		<category><![CDATA[editor-in-chief]]></category>
		<category><![CDATA[Hana Biosciences]]></category>
		<category><![CDATA[investor group]]></category>
		<category><![CDATA[lead product candidate]]></category>
		<category><![CDATA[lymphoblastic lymphoma]]></category>
		<category><![CDATA[Marquibo]]></category>
		<category><![CDATA[Orbimed Advisors Llc;]]></category>
		<category><![CDATA[Perceptive Life Sciences Master Fund Ltd.]]></category>
		<category><![CDATA[Piper Jaffray and Co.]]></category>
		<category><![CDATA[Steven R. Deitcher]]></category>
		<category><![CDATA[USD]]></category>

		<guid isPermaLink="false">http://Blog.QualityStocks.net/?p=18398</guid>
		<description><![CDATA[Hana Biosciences is a company that is clearly moving in the right direction.  The company&#8217;s lead product candidate, Marquibo, has been developed to help all cancer patients battle the deadly disease and with news released today, the concept has a great deal of backing.
The young California Company announced there is a definite agreement in [...]]]></description>
		<wfw:commentRss>http://www.straightstocks.com/investing-lessons/hana-biosciences-inc-hnab-ob-announces-12-4-million-private-placement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pfizer-Wyeth Thoughts</title>
		<link>http://www.straightstocks.com/investing-in-energy-markets/pfizer-wyeth-thoughts/</link>
		<comments>http://www.straightstocks.com/investing-in-energy-markets/pfizer-wyeth-thoughts/#comments</comments>
		<pubDate>Fri, 23 Jan 2009 15:36:00 +0000</pubDate>
		<dc:creator>Michael E. Brisky</dc:creator>
				<category><![CDATA[Energy Markets]]></category>
		<category><![CDATA[Market Commentary]]></category>
		<category><![CDATA[bloomberg]]></category>
		<category><![CDATA[FULL]]></category>
		<category><![CDATA[huge pharmaceutical;]]></category>
		<category><![CDATA[Jeff Kindlerspan style;]]></category>
		<category><![CDATA[Leerink Swann;]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[Madison]]></category>
		<category><![CDATA[michael brisky]]></category>
		<category><![CDATA[New Jersey]]></category>
		<category><![CDATA[New York]]></category>
		<category><![CDATA[Orbimed Advisors Llc;]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[pneumonia]]></category>
		<category><![CDATA[Samuel Isaly;]]></category>
		<category><![CDATA[Seamus Fernandez;]]></category>
		<category><![CDATA[USD]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">tag:blogger.com,1999:blog-819581243324579563.post-7893940601515897975</guid>
		<description><![CDATA[The rumors are back that Pfizer is negotiating to buy Wyeth, which would create a huge pharmaceutical company. br /br /blockquotePfizer, based in New York, has been negotiating with Madison, New  Jersey-based Wyeth for months, one person said. A combination would create a  drugmaker with annual sales of more than $70  billion, and best-selling medicines that include Pfizer’s cholesterol pill  Lipitor, the world’s top-selling medicine with $12.7 billion in 2007 sales, and  Wyeth’s Prevnar vaccine against pneumonia. /blockquotebr /br /Based on similar deals, the figures thrown around would put this deal around $60 billion. It is still speculation, and a few factors could push it higher.  There are a few ways to look at this.  To begin, I'm a Wyeth shareholder so I already am a believer in the quality of Wyeth.  I think for Wyeth, a deal at $60 billion would be a little light.  Its not a deal they need to do.  They have a nice cash position and a good lineup of products.  Pfizer needs this deal a lot more.  They have Lipitor expiring and haven't been able to create new earnings outside of acquisitions.  It seems their management may be feeling the pressure to do some kind of a deal:br /br /blockquoteKindler has been under pressure from investors and analysts to make a major  acquisition as Lipitor sales fade in advance of the patent expiration. Kindler’s  efforts to reorganize the company by firing more than 15,000 employees,  including top management, hasn’t been enough, Samuel Isaly, managing partner at Orbimed Advisors Llc, said in  an interview.   p“Pfizer is desperate in my opinion -- or should be desperate,” Isaly said. "Jeff Kindlerspan style="text-decoration: underline;"/span will be terminated if he doesn’t do something  soon, so he has really got to move it and we wouldn’t be surprised to see a  major move.” /p/blockquotepbr //ppDuring this period where credit is hard to come by, you might think it would be difficult to finance a deal this big.  But if there are any companies that can pull it off right now, it is pharmaceutical companies.  They have the most stable earnings and balance sheets right now.  /pblockquote“There are very few companies in the world that are going to get money in  this environment, but these companies are going to get it,” Ryan said in a Jan.  20 telephone interview. “When we have conversations in private with these CFOs,  I am being told they have access to money.”  pPfizer may have to cut its dividend to finance the acquisition, said Leerink  Swann analyst Seamus Fernandez in a note to clients today. The benefit to the  share price from the deal would still be worth it for investors, he said. /p/blockquotepbr //ppSo we'll see where this goes.  The deal could go higher, or the deal could fall apart.  If I were Wyeth, I wouldn't rush into anything.  They don't need this deal and it should be a little sweeter for shareholders, in my opinion. br //ppDisclosure: Long WYE/ppa href="http://www.bloomberg.com/apps/news?pid=20601087amp;sid=aKHH_cnREo2gamp;refer=home"Bloomberg Article/a.br //p]]></description>
		<wfw:commentRss>http://www.straightstocks.com/investing-in-energy-markets/pfizer-wyeth-thoughts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
